Neurodegenerative changes in patients with clinical history of bipolar disorders

Neuropathology

Volumn 35, Issue 3, 2015, Pages 245-253

  Shioya, Ayako ^a,d   Saito, Yuko ^a   Arima, Kunimasa ^a,g   Kakuta, Yukio ^e   Yuzuriha, Takefumi ^f   Tanaka, Noriko ^b   Murayama, Shigeo ^c   Tamaoka, Akira ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e YOKOHAMA ROSAI HOSPITAL   (Japan)

^f National Hospital Organization Hizen Psychiatric Center   (Japan)

^g Komoro Kogen Hospital   (Japan)

Author keywords

Argyrophilic grain; Chronic traumatic encephalopathy; Lithium carbonate; Mood disorder; Tau

Indexed keywords

ANTIBODY; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BIOLOGICAL MARKER; LEVODOPA; LITHIUM CARBONATE; NEUROLEPTIC AGENT; PARAFFIN;

ADULT; AGED; AMYGDALOID NUCLEUS; ARGYROPHILIC GRAIN DISEASE; ARTICLE; AUTOPSY; BIPOLAR DISORDER; BRAIN INFARCTION; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOHISTOCHEMISTRY; LIMBIC CORTEX; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; MENTAL PATIENT; MIDDLE AGED; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSONISM; PRIORITY JOURNAL; THALAMUS; TISSUE SECTION; VERY ELDERLY; BRAIN; CASE REPORT; COMPLICATION; PATHOLOGY;

AGED; AGED, 80 AND OVER; BIPOLAR DISORDER; BRAIN; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES;

EID: 84930064579     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12191     Document Type: Article

References (27)

1. Townsend J, Altshuler LL. Emotion processing and regulation in bipolar disorder: a review. Bipolar Disord 2012; 14: 326-339.
2. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007; 61: 3-19.
3. Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351: 476-486.
4. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996; 93: 8455-8459.
5. Massot O, Rousselle JC, Fillion MP, Januel D, Plantefol M, Fillion G. 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders. Neuropsychopharmacology 1999; 21: 530-541.
6. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci U S A 1998; 95: 8363-8368.
7. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999; 46: 929-940.
8. Shimada K, Motoi Y, Ishiguro K etal. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis 2012; 46: 101-108.
9. Prickaerts J, Moechars D, Cryns K etal. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006; 26: 9022-9029.
10. Dokucu ME, Yu L, Taghert PH. Lithium- and valproate-induced alterations in circadian locomotor behavior in Drosophila. Neuropsychopharmacology 2005; 30: 2216-2224.
11. Hong M, Chen DC, Klein PS, Lee VM. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997; 272: 25326-25332.
12. Braak H, Braak E. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 1987; 76: 124-127.
13. Tolnay M, Spillantini MG, Goedert M, Ulrich J, Langui D, Probst A. Argyrophilic grain disease: widespread hyperphosphorylation of tau protein in limbic neurons. Acta neuropathologica 1997; 93: 477-484.
14. Togo T, Sahara N, Yen SH etal. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002; 61: 547-556.
15. Ikeda K, Akiyama H, Arai T, Matsushita M, Tsuchiya K, Miyazaki H. Clinical aspects of argyrophilic grain disease. Clin Neuropathol 2000; 19: 278-284.
16. McKee AC, Stern RA, Nowinski CJ etal. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136: 43-64.
17. Saito Y, Ruberu NN, Sawabe M etal. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911-918.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
19. Fumimura Y, Ikemura M, Saito Y etal. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 2007; 66: 354-362.
20. Saito Y, Kawashima A, Ruberu NN etal. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003; 62: 644-654.
21. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 1991; 82: 239-259.
22. McKeith IG, Dickson DW, Lowe J etal. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
23. Hatsuta H, Saito Y, Sawabe M, Mori H, Murayama S. Staging of amyloid angiopathy in human aging brain. Neuropathology 2007; 27: 191.
24. Dickson DW, Bergeron C, Chin SS etal. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935-946.
25. Nagao S, Yokota O, Ikeda C etal. Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. Eur Arch Psychiatry Clin Neurosci 2014; 264: 317-331.
26. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease? Clin Neuropathol 1984; 3: 185-192.
27. Jellinger KA. Lewy body/alpha-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study. Acta Neuropathologica 2009; 117: 423-427.